Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Onco-Nurse Academy™: Evolving HER2 Treatment Approaches Across Tumor Types

Release Date: May 10, 2021
Expiration Date: May 10, 2022

Activity Overview

HER2 amplification has been increasingly recognized as a frequent abnormality, not only in lung and breast cancer but also in gastroesophageal and colorectal cancers. HER2 genetic testing is essential for determining which patients will benefit from treatment with HER2-targeted agents; however, HER2 testing guidelines vary among the different tumor types. The utilization of HER2-targeted agents for the treatment of these cancers has increased. Novel HER2-targeted agents include the monoclonal antibodies trastuzumab, pertuzumab, and margetuximab; the antibody-drug conjugates ado-trastuzumab emtansine and fam-trastuzumab deruxtecan; and the tyrosine kinase inhibitors lapatinib, neratinib, and tucatinib. Importantly, each of these drug families is associated with different adverse events (AEs) and, thus, requires individualized monitoring as well as mitigation and treatment strategies.

This online, on-demand virtual symposium is specifically designed to educate and empower oncology professionals who provide health care to patients with breast, gastrointestinal, colorectal, and lung cancers. It will feature expert faculty sharing data and clinical insights on the role and mechanistic activity of HER2-targeted therapies used to treat these tumor types, clinical profiles of available agents, strategies for managing treatment-related toxicities, and emerging data on novel agents that are being investigated. The webcast will feature 4 segments, each focusing on a different aspect of the management approach and each including a patient case vignette, brief presentations on key findings and patient counseling messages, and a panel discussion that summarizes key points and offers guidance on implementation of best practices in the clinic.

This educational activity is an archive of a live virtual symposium held on April 22, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward nurses and other health care professionals who treat patients with cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to

Explain the mechanistic rationale that informs the application of HER2-directed therapy in cancer care
Discuss recent safety and efficacy data pertaining to the use of HER2-directed therapies for the treatment of breast, lung, and gastrointestinal cancers
Devise strategies to promptly identify, mitigate, and manage treatment-related toxicities in patients with cancer being treated with HER2-directed therapies
Determine effective counseling strategies to assist patients’ understanding of the rationale for their cancer treatment plan and management of treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible entities.

Co-Chairs

Ian Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:Grant: Genentech/Hoffmann-LaRoche, Pfizer; Consultant: Daiichi Sankyo, Genentech/Hoffmann-La Roche, MacroGenics, Seagen, AstraZeneca; Other: Novartis Pharmaceuticals, Merck & Co (Data Safety Monitoring Boards with Honoraria)

Elahe Salehi, NP
Director, Advanced Practice Nursing
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Elahe Salehi, NP, has no relevant financial relationships with ineligible companies.

Faculty

Kelley A. Rone, DNP, AGNP-C
Advanced Practice Nurse
Gastrointestinal Oncology Division of Hematology and Oncology
Mayo Clinic
Phoenix, AZ

Disclosures: Kelley A. Rone, DNP, AGNP-C, has no relevant financial relationships with ineligible companies.

Beth Sandy, MSN, CRNP
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Speaker’s Bureau: AstraZeneca, Merck & Co, Takeda Pharmaceutical Company.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.